Fibrocell Science, Inc. to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders

EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference to be held on Tuesday, December 6, 2011 at the St. Regis Hotel in San Francisco.

Fibrocell’s presentation is scheduled for 3:40 p.m. Pacific Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company's website at www.fibrocellscience.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.



CONTACT:

Media
Marina Maher Communications
Jessica Morrison
212-485-6806
[email protected]
or
Investors
ICR, LLC
Sherry Bertner
Managing Director
646-277-1247
[email protected]

KEYWORDS:   United States  North America  California  Pennsylvania

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Pharmaceutical  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.